Novartis, Incyte strike potential $1B deal

Wilmington, DE-based Incyte announced today that it will get a hefty $150 million up front and a $60 million milestone payment on a new licensing deal with Novartis that could be worth more than $1 billion. In one fell swoop, Novartis has added two hematology-oncology drug candidates to its pipeline.

Novartis gains ex-U.S rights to INCB18424, an oral JAK1/JAK2 inhibitor that is in Phase III development for myelofibrosis, a condition that can cause bone marrow failure, splenic enlargement and debilitating constitutional symptoms. The agreement "puts us in a strong position to transition Incyte into a successful commercial company with sufficient resources to continue to advance other promising compounds in our pipeline," notes Incyte CEO Paul Friedman, who adds in a statement that his company will retain U.S. rights to the drug. The deal also covers INCB28060, an oral cMET inhibitor that is about to enter Phase I development as a potential treatment for multiple cancers. Today's agreement gives Novartis global rights to that drug.

If development and commercialization milestones are met, Incyte could receive additional payments of up to $1.1 billion. The company also gets tiered, double-digit royalty payments on future ex-U.S. INCB18424 sales. Novartis will be responsible for all costs and activities for the cMET inhibitor after the Phase I clinical trial. Incyte is eligible to receive royalties on future sales of INCB28060 and has retained an option to co-develop and co-promote the candidate.

- here's Incyte's release
- read the Reuters report

Suggested Articles

A few years ago, one of our Fierce editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked.

Pfizer's eczema hopeful has been building its case to challenge Sanofi and Regeneron's Dupixent, but safety issues could stand in its way.

Cedrik Britten, M.D., becomes the biotech’s new chief medical officer to help run its adoptive cell therapy and TCR bispecifics platform.